Navigation Links
Merck Serono et l'Institut Feinstein vont s'associer pour développer un programme pré-clinique portant sur les maladies inflammatoires
Date:1/29/2013

vec l'Institut Feinstein permettra à Merck Serono de renforcer davantage ses recherches sur les mécanismes d'action alternatifs pour le traitement du LED.

A propos du lupus érythémateux disséminé (LED)

Le lupus érythémateux disséminé est une maladie inflammatoire chronique au cours de laquelle le système immunitaire attaque les propres tissus et organes du malade. Le LED est la forme la plus fréquente de lupus et peut être à l'origine de douleurs articulaires avec œdème, d'éruptions cutanées, de fatigue extrême et d'atteinte rénale. Le diagnostic est généralement porté chez des patients âgés de 20 à 40 ans, le plus souvent des femmes. Plus de 600 000[1] personnes dans le monde souffriraient de lupus érythémateux disséminé.

[1]Systemic Lupus Erythematosus, Decision Resources. Janvier 2011

A propos de l'Institut Feinstein pour la Recherche Médicale

L'Institut Feinstein pour la Recherche Médicale dont le siège est basé à Manhasset, accueille des experts scientifiques internationaux spécialisés dans la maladie de Parkinson, la maladie d'Alzheimer, certains troubles psychiatriques, la polyarthrite rhumatoïde, le lupus, la septicémie, l'hypertension artérielle pulmonaire, les leucémies, la génétique, la neuro-immunologie et la chimie médicale. L'Institut Feinstein, figure parmi les institutions bénéficiant du soutien du National Institutes of Health. Pour obtenir plus d'informations, veuillez consulter le site : http://www.FeinsteinInstitute.org

A propos de Merck Serono

Merck Serono est la division biopharmaceutique de Merck KGaA. Merck Serono, dont le siège est à Darmstadt (Allemagne),
'/>"/>

SOURCE Merck Serono S A
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
3. Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
4. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
5. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
6. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Man-made pores mimic important features of natural pores
9. Building Wireless Solution More Important than Ever with New Tablets
10. Carbon nanotubes can double growth of cell cultures important in industry
11. Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... and chief executive officer with Radiation Shield Technologies (RST), ... the Radiological Society of North America (RSNA) 94th Scientific ... a.m. to 5 p.m. Nov. 30 to Dec. 5 ... Dr., Chicago. North Building, Hall B. Booth No.: 9517. ...
... DNA Mini Portrait™ is this years, most unique must-have gift , ... ... of custom portraits made from the customers, DNA, launch DNA Mini Portraits™, ... and pop culture. DNA Minis are the most personal and unique ...
... Calif., and SEATTLE, Nov. 26 Spectrum,Pharmaceuticals, Inc. ... Inc.,(Nasdaq: CTIC )(MTA: CTIC) announced today ... 50/50 owned joint venture, RIT Oncology LLC, to ... States.,ZEVALIN, a radioimmunotherapeutic (RIT), is currently marketed in ...
Cached Biology Technology: New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric 2DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 3Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 4Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 5Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 6Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 7Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 8
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
(Date:7/10/2014)... for Basic Science (IBS), the main organization of the ... has announced that a group of researchers, led by ... in the field of optogenetics that can remotely control ... technology "OptoTrk" and it has succeeded with neuronal differentiation ... is that it requires only light to activate neuronal ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2New optogenetic tool for controlling neuronal signalling by blue light 2
... N.M. A matchbook-sized atomic clock 100 times smaller than ... researchers at Symmetricom Inc. Draper Laboratory and Sandia National Laboratories. ... 1.5 inches on a side and less than a half-inch ... its predecessors. Instead of 10 watts, it uses only 100 ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... today announced that Edmund C. Reiter has resigned, effective April ... of the board of the company citing personal reasons.   ... General Counsel have been named co-CEOs and co-Presidents on an ...
... April 11, 2011 MiMedx Group, Inc. (OTCBB: MDXG), ... biomaterial-based products and bioimplants processed from human amniotic membrane, ... product, EpiFix™, a biologic implant specifically processed to offer ... options. The Company also announces the hiring of Frank ...
Cached Biology News:World's smallest atomic clock on sale 2World's smallest atomic clock on sale 3World's smallest atomic clock on sale 4Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: